Lumida
/AMN
⌘K
AMN Healthcare Services Inc

AMN Healthcare Services Inc

AMN
$33.34USD+0.88%+0.29 today

MARKET CAP

1.3B

P/E (TTM)

FWD P/E

DAY RANGE

$33 – $34

52W RANGE

$15
$37

AI Summary

Stalk
StalkMedium

AMN remains in a Stage 2 markup within a solid long-term uptrend. Price is consolidating between support and resistance near the short- and mid-term EMAs, with neutral momentum and declining volume arguing for patience before committing. We will defer buying until either a clear breakout above the recent highs is confirmed or a shallow pullback into the rising EMA zone is absorbed, aligning with the High Momentum strategy’s emphasis on shallow retracements into trend continuation.

  • Q2 revenue $673M and adjusted EPS $0.77 exceeded guidance; positive earnings revisions.
  • Nurse & Allied Solutions revenue $422M, up 11% YoY, shows strong segment demand.
  • Negative profitability metrics highlight operational inefficiency and low returns.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$4.0B$5.2B$3.8B$3.0B$2.7B
YoY %+66.4%+31.6%-27.7%-21.3%-8.5%
P / Sales1.5x0.9x0.8x0.3x0.2x
EV / Sales1.9x1.2x1.3x0.9x0.7x
Gross Profit, Adj.$1.3B$1.7B$1.2B$919.4M$774.1M
YoY %+65.4%+31.1%-27.2%-26.4%-15.8%
Margin %32.9%32.7%33.0%30.8%28.3%
EV / Gross Profit5.9x3.8x4.1x2.8x2.6x
EBITDA, Adj.$581.7M$784.2M$507.2M$293.6M$189.8M
YoY %+138.9%+34.8%-35.3%-42.1%-35.4%
Margin %14.6%15.0%13.4%9.8%7.0%
EV / EBITDA13.2x8.3x10.1x8.9x10.7x
EBIT$478.0M$647.1M$338.4M$-102.7M$-94.6M
YoY %+220.2%+35.4%-47.7%-130.3%+7.9%
Margin %12.0%12.3%8.9%-3.4%-3.5%
EV / EBIT16.0x10.1x15.1x-25.4x-21.4x
Net Income$327.4M$444.1M$210.7M$-147.0M$-95.7M
YoY %+363.3%+35.6%-52.6%-169.8%+34.9%
Net Margin8.2%8.5%5.6%-4.9%-3.5%
EPS (GAAP)$6.81$9.90$5.36-$3.85-$2.48
YoY %+360.1%+45.4%-45.9%-171.8%+35.6%